Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly (NYSE:LLY) climbed 3% in premarket trading Thursday after unveiling landmark Phase 3 data for its experimental ...

Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed ...

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

USA: A first-in-class triple hormone receptor agonist, retatrutide, has demonstrated striking reductions in body weight along ...

Topline phase 3 results show retatrutide led to meaningful weight reduction and pain relief in adults with overweight or obesity and knee OA.